OR WAIT 15 SECS
Volume 12, Issue 17
Biotage AB has announced the purchase of shares in the Danish biomolecule company Chreto Aps, representing a significant investment into the area of drug development.
Biotage AB (Uppsala, Sweden) has announced the purchase of shares in the Danish biomolecule company Chreto Aps, representing a significant investment into the area of drug development.
Biomolecules are one of the fastest growing areas in drug development today, offering potential treatments to medical conditions poorly served by traditional pharmaceuticals.
“This investment makes an exciting part of our long-term strategic efforts,” explained Torben Jörgensen, CEO of Biotage. “We already have products for drug development based on peptides and are now taking one step further towards strengthening Biotage’s future offering in the biomolecule purification area.”
The deal, which sees Biotage own approximately 22% of Chreto, allows Biotage access to a wealth of biomolecule purification knowledge, as well as novel and patent protected technology.
For more information on Biotage please visit: www.biotage.com